Dimitris Rizopoulos, Jeremy Mg Taylor, Grigorios Papageorgiou, Todd M Morgan
{"title":"Using joint models for longitudinal and time-to-event data to investigate the causal effect of salvage therapy after prostatectomy.","authors":"Dimitris Rizopoulos, Jeremy Mg Taylor, Grigorios Papageorgiou, Todd M Morgan","doi":"10.1177/09622802241239003","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer patients who undergo prostatectomy are closely monitored for recurrence and metastasis using routine prostate-specific antigen measurements. When prostate-specific antigen levels rise, salvage therapies are recommended in order to decrease the risk of metastasis. However, due to the side effects of these therapies and to avoid over-treatment, it is important to understand which patients and when to initiate these salvage therapies. In this work, we use the University of Michigan Prostatectomy Registry Data to tackle this question. Due to the observational nature of this data, we face the challenge that prostate-specific antigen is simultaneously a time-varying confounder and an intermediate variable for salvage therapy. We define different causal salvage therapy effects defined conditionally on different specifications of the longitudinal prostate-specific antigen history. We then illustrate how these effects can be estimated using the framework of joint models for longitudinal and time-to-event data. All proposed methodology is implemented in the freely-available R package <b>JMbayes2</b>.</p>","PeriodicalId":22038,"journal":{"name":"Statistical Methods in Medical Research","volume":" ","pages":"894-908"},"PeriodicalIF":1.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041089/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistical Methods in Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09622802241239003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate cancer patients who undergo prostatectomy are closely monitored for recurrence and metastasis using routine prostate-specific antigen measurements. When prostate-specific antigen levels rise, salvage therapies are recommended in order to decrease the risk of metastasis. However, due to the side effects of these therapies and to avoid over-treatment, it is important to understand which patients and when to initiate these salvage therapies. In this work, we use the University of Michigan Prostatectomy Registry Data to tackle this question. Due to the observational nature of this data, we face the challenge that prostate-specific antigen is simultaneously a time-varying confounder and an intermediate variable for salvage therapy. We define different causal salvage therapy effects defined conditionally on different specifications of the longitudinal prostate-specific antigen history. We then illustrate how these effects can be estimated using the framework of joint models for longitudinal and time-to-event data. All proposed methodology is implemented in the freely-available R package JMbayes2.
对接受前列腺切除术的前列腺癌患者进行常规前列腺特异性抗原测量,密切监测复发和转移情况。当前列腺特异性抗原水平升高时,建议采用挽救疗法,以降低转移风险。然而,由于这些疗法存在副作用,为了避免过度治疗,了解哪些患者以及何时启动这些挽救性疗法非常重要。在这项研究中,我们利用密歇根大学前列腺切除术登记数据来解决这个问题。由于该数据的观察性质,我们面临的挑战是前列腺特异性抗原既是时变混杂因素,又是挽救疗法的中间变量。我们根据纵向前列腺特异性抗原历史的不同规格定义了不同的挽救治疗因果效应。然后,我们说明了如何利用纵向数据和时间到事件数据的联合模型框架来估算这些效应。所有建议的方法都在免费提供的 R 软件包 JMbayes2 中实现。
期刊介绍:
Statistical Methods in Medical Research is a peer reviewed scholarly journal and is the leading vehicle for articles in all the main areas of medical statistics and an essential reference for all medical statisticians. This unique journal is devoted solely to statistics and medicine and aims to keep professionals abreast of the many powerful statistical techniques now available to the medical profession. This journal is a member of the Committee on Publication Ethics (COPE)